Typical clinico-pharmacological article
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
Angioprotector, reduces the permeability of the vascular wall, is an inhibitor of free radical processes, an antihypoxant and an antioxidant.
Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cAMP and cGMP) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of developing hemorrhages, contributes to their resorption. Expands coronary vessels, in the acute period of myocardial infarction limits the magnitude of the focus of necrosis, improves the contractility of the heart and the function of its conductive system. With increased blood pressure has an antihypertensive effect. In acute ischemic impairment of cerebral circulation reduces the severity of neurologic symptoms, increases tissue resistance to hypoxia and ischemia.
It has retinoprotective properties, protects the retina from the damaging effect of high-intensity light, promotes resorption of intraocular hemorrhages, improves microcirculation of the eye.
As part of complex therapy: the consequences of cerebrovascular disorders of ischemic and hemorrhagic nature, CCT, postoperative epi- and subdural hematoma;acute myocardial infarction, prevention of reperfusion syndrome, unstable angina.
Subconjunctival and intraocular hemorrhage, angioretinopathy (including diabetic), chorioretinal dystrophy (including atherosclerotic genesis), dystrophic keratitis, retinal vascular thrombosis, complications of myopia, protection of the cornea (when wearing contact lenses) and retina of the eye from exposure light of high intensity (laser and sunburn, with laserocoagulation), trauma, inflammation and burn of the cornea, cataracts (including prophylaxis in people over 40), operative eye surgery, condition after surgery for g laucoma with detachment of the choroid.
In neurology and cardiology, intravenous drip (20-40 cap / min), 20-30 ml of a 3% solution (600-900 mg) 1-3 times a day for 5-15 days (the drug is previously diluted in 200 ml 0.9% NaCl solution or 5% dextrose solution). The duration of treatment depends on the course of the disease. Subsequently, they switch to the / m administration - 3-5 ml of a 3% solution 2-3 times a day for 10-30 days.
In ophthalmology - subconjunctival or parabulbar, once a day or every other day. Subconjunctival - 0.2-0.5 ml of 1% solution (2-5 mg), parabulbar - 0.5-1 ml of 1% solution (5-1 mg). Duration of treatment - 10-30 days; it is possible to repeat the course 2-3 times a year.
If necessary - retrobulbarno for 0.5-1 ml of 1% solution once a day for 10-15 days.
To protect the retina in lacerocoagulation (including with limiting and destructive coagulation of tumors) - parabulbar or retrobulbarno for 0.5-1 ml of 1% solution for 24 hours and 1 hour before coagulation; then in the same doses (0.5 ml of 1% solution) once a day for 2-10 days.
Short-term excitation, drowsiness, increased blood pressure, allergic reactions (skin rashes, etc.), local reactions - pain, burning, itching, hyperemia, densification of paraorbital tissues (resolves itself).
PREGNANCY AND LACTATION
Contraindicated in pregnancy.
Treatment should be carried out under the control of blood pressure and blood coagulability.
Pharmaceutically incompatible with other medicines.